Real-world Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis
Authors:
- Subhash TodiSTSubhash Todi
- Prachee SathePSPrachee Sathe
- Venkatasubramanian RamasubramanianVRVenkatasubramanian Ramasubramanian
- Subramanian SwaminathanSSSubramanian Swaminathan
- Deepak TalwarDTDeepak Talwar
- Parikshit PrayagPPParikshit Prayag
- Polati Vishnu RaoPRPolati Vishnu Rao
- Kirti SabnisKSKirti Sabnis
- Shweta KamatSKShweta Kamat
- Akshata ManeAMAkshata Mane
- Harish ThanusubramanianHTHarish Thanusubramanian
Preprint
- 12 June 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
There is limited real-world data from India examining the treatment characteristics, safety, and efficacy of ceftazidime-avibactam against Gram-negative organisms especially multidrug-resistant pathogens including Carbapenem-Resistant Enterobacterales and Carbapenem-Resistant Pseudomonas. In this retrospective study, the real-world treatment patterns, effectiveness, and safety of ceftazidime-avibactam in treating Gram- negative infections were assessed. Data was extracted from electronic health records of adult patients admitted to the hospital with documented Gram-negative infection who had received treatment for at least 48 hours with ceftazidime-avibactam as a part of routine clinical management. Among the 189 patients, on day 3, clinical symptoms improvement was recorded in 79.6% of patients. Clinical success was achieved in 79.5% and 76.3% of assessed patients on day 7 and day 14/End-of-treatment, respectively. Microbiological success was reported in 76% of patients on day 7 and in 60.3% of patients on day 14 or EOT. The mean treatment duration of ceftazidime-avibactam therapy was 6.92 (± 4.1) days. No new safety concerns were identified. In conclusion, this study provides real-world evidence on treatment patterns and clinical outcomes associated with ceftazidime-avibactam in India, complementing the previously reported literature. The results suggest ceftazidime-avibactam is an effective and tolerable option for the management of Gram-negative infections in critically ill patients.Keywords
All Related Versions
- Version 1, 2024-06-12, Preprints
- Published version: Cureus, 16 (9).
This publication has 22 references indexed in Scilit:
- The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM StudyInfectious Diseases and Therapy, 2023
- Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant EnterobacteralesClinical Infectious Diseases, 2022
- Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)Journal of Antimicrobial Chemotherapy, 2022
- Clinical outcomes of ceftazidime-avibactam versus meropenem in Indian patients with nosocomial pneumonia: Subset analysis from the REPROVE studyIndian Journal of Medical Microbiology, 2021
- The Mortality Burden of Multidrug-resistant Pathogens in India: A Retrospective, Observational StudyClinical Infectious Diseases, 2018
- Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial InfectionsDrugs, 2018
- The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global MenaceThe Journal of Infectious Diseases, 2017
- The β‐Lactams Strike Back: Ceftazidime‐AvibactamPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Carbapenem-Resistant Enterobacteriaceae: Epidemiology and PreventionClinical Infectious Diseases, 2011
- Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control studyJournal of Antimicrobial Chemotherapy, 2007